Astellas has said it will book a $170 million ... both in early-stage clinical development – along with DMD gene therapies AT702, AT751 and AT753. The full financial impact of the delay to ...

In light of this, Astellas, a global pharmaceutical company based in Tokyo, Japan, has set a long-term goal of advancing cell and gene therapies for treating eye diseases. Degenerative eye ...

D Molecular Therapeutics, Inc.’s FDMT share price has dipped by 5.25%, which has investors questioning if this is right time to buy.

Initiate coverage on Taysha Gene Therapies with a Sell rating due to ... This is particularly concerning to us as Astellas previously walked away from TSHA 120 in giant axonal neuropathy due ...

Astellas’ gene therapy for rare disease ... along with decisions to abandon other pipeline projects, including three gene therapies for Duchenne muscular dystrophy. The company clearly has ...

Satinder Rawat, PhD, has an extensive background in business development, licensing, and strategic partnerships, with a focus on gene therapies ... including Pfizer, Astellas, Sarepta and BridgeBio.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

AviadoBio, a pioneering gene therapy company dedicated to developing ... who continue to inspire our commitment to advancing research for therapies that may slow or stop the progression of this ...

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...